Rezolute, Inc. (NASDAQ: RZLT) reported a net loss of $22.8 million for the three months ended December 31, 2025, a widening from the $15.7 million loss recorded in the same period a year earlier. The company’s earnings per share fell to $‑0.22, missing the consensus estimate of $‑0.16 by $0.06, a miss that reflects the impact of one‑time severance costs and higher clinical‑trial spending.
Research and development expenses rose to $14.3 million, up $1.7 million from $12.6 million in Q2 2025, driven by intensified investment in the flagship antibody ersodetug and related manufacturing activities. General and administrative costs more than doubled to $9.9 million, up $5.4 million from $4.5 million a year earlier, largely due to professional fees and the $1.5 million severance payment associated with a December 2025 workforce reduction. These expense increases, combined with the absence of revenue, explain the broadened loss.
Cash, cash equivalents, and marketable securities stood at $132.9 million as of December 31, 2025, down from $167.9 million at June 30, 2025. Management indicated that the current liquidity position is sufficient to fund operations for at least 12 months, providing a modest runway amid the company’s heavy investment cycle.
The results were tempered by the failure of the Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism, which did not meet its primary or key secondary endpoints. In contrast, the company highlighted progress in the upLIFT Phase 3 trial for tumor hyperinsulinism, with topline data expected in the second half of 2026, offering a potential upside that may offset the sunRIZE setback.
Analysts noted the EPS miss and the trial failure, but the company’s cash runway and the upcoming upLIFT readout were cited as mitigating factors. The market reaction was modest, with the stock trading near $3.63 on the day of the release, reflecting a cautious balance between the negative trial news and the company’s continued focus on high‑potential indications.
Management reiterated confidence in the company’s cash position and emphasized the strategic importance of the upLIFT trial. While acknowledging the sunRIZE disappointment, executives underscored their belief in ersodetug’s pharmacologic activity and the potential for future regulatory engagement. The company’s outlook remains focused on advancing the upLIFT study and maintaining financial flexibility for the next 12 months.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.